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Abstract
Background Up to 4 % of patients presenting with a hip
fracture may be on warfarin at admission. There is little
consensus on the timing, dosage or route of vitamin K
administration. We aimed to evaluate the impact of a
locally developed, evidence-based protocol for periopera-
tive warfarin management on the admission-to-operation
time (AOT) in hip fracture patients.
Materials and methods Clinical and demographic data
were collected prospectively for hip fracture patients who
were on warfarin at the time of admission (post-protocol
group) and compared to a historical control group of
patients who were on warfarin before implementation of
the protocol (pre-protocol group). Univariate analysis was
undertaken to identify any significant differences between
the two groups.
Results Twenty-seven patients in the pre-protocol group
(27/616, 4.4 %) and 40 patients in the post-protocol group
(4.7 %, 40/855) were on warfarin at admission. There was
a significant reduction in the median AOT from 73 h (IQR
46–105) to 37.7 h (IQR 28–45) after implementation of the
warfarin protocol (p \ 0.001). The proportion of patients
operated on within 48 h of admission increased from 30 %
(8/27) in the pre-protocol group to 80 % (32/40) in the
post-protocol group (p \ 0.001). No significant differences
in hospital length of stay (p = 0.77) or the postoperative
warfarin recommencement time (p = 0.90) were noted
between the two groups.
Conclusion Implementation of a perioperative warfarin
management protocol can expedite surgery in hip fracture
patients, but did not reduce hospital stay in our cohort,
possibly because of a delay in recommencing warfarin in
these patients postoperatively.
Level of evidence Level III.
Keywords Warfarin  Anticoagulation  Trauma
surgery  Hip fracture  Vitamin K  Protocol  Elderly
Introduction
Timely preoperative optimisation of hip fracture patients is
critical in allowing urgent surgery [1–4]. Delays in surgical
management are associated with poor outcomes. It is
estimated that up to 4 % of these patients are on an anti-
coagulants such as warfarin for a variety of medical con-
ditions [5, 6]. The British Society of Haematology
recommends preoperative discontinuation of warfarin and
administration of vitamin K in order to expedite INR
reduction in these patients [7]. An international normalised
ratio (INR) of \1.5 is required before hip surgery can
proceed safely [4]. Re-warfarinisation is recommended on
the first postoperative day, provided adequate haemostasis
has been achieved during surgery [7]. Existing guidelines
on vitamin K administration are ambiguous. As a result
there is wide variation in clinical practice across the UK [8]
with little or no consensus on the timing, dosage or route of
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administration of vitamin K prior to hip fracture surgery or
recommencement of warfarin post-surgery [9–12]. We
hypothesised that implementation of a locally developed,
evidence based protocol for perioperative warfarin reversal
and postoperative re-warfarinisation would significantly
reduce the admission-to-operation time (AOT) in hip
fracture patients. We also aimed to determine if imple-
mentation of such a protocol would lead to a reduction in
the postoperative warfarin recommencement time and
overall length of stay in hospital.
Materials and methods
The study was approved by the clinical governance team at
our institution. It was confirmed that the project fulfilled the
criteria of a clinical audit as defined in the NHS National
Research Ethics Service document entitled ‘Defining
Research’ [13] and formal ethical approval from the NHS
research and ethics committee was therefore not deemed
necessary. The study was performed in accordance with the
ethical standards of the 1964 Declaration of Helsinki as
revised in 2000. Since the study involved evaluation of the
routine clinical care received by hip fracture patients, for-
mal consent from individual patients was not warranted,
and was waived by the clinical governance team. However,
implied consent was sought through information leaflets by
making all patients aware of continued clinical auditing to
improve clinical care received by patients.
A retrospective case series evaluation conducted at our
institution in July 2010 showed a significant delay in the
operative fixation of hip fractures in patients on warfarin
therapy at the time of admission. This led to a multidisci-
plinary consultation involving orthopaedic surgeons, hae-
matologists and medical and nursing health staff with
subsequent development of a local protocol for warfarin
management in hip fracture patients. This protocol was based
on guidance issued by the British Society of Haematology [7]
and American Heart Association [11] and adopted an algo-
rithm-based approach towards preoperative warfarin dis-
continuation (Fig. 1) and postoperative recommencement of
warfarin in hip fracture patients (Fig. 2). The protocol was
implemented at our institution in August 2010. The pro-
spective arm of the study directly followed the historic case
series. All patients with an INR B1.5 were operated on the
next available trauma list. We hypothesised that imple-
mentation of a locally developed perioperative warfarin
management protocol would lead to a significant reduction in
the AOT for hip fracture patients on warfarin therapy at
admission. We defined AOT as the interval between
admission of a patient into the emergency department or
diagnosis of fracture if the patient was already in hospital (in-
patient injury) and start of induction of anaesthesia.
All hip-fracture patients that underwent hip fracture
surgery at our institution were identified for inclusion into
the study from our locally developed ‘hospital hip-fracture
database’. Demographic, clinical and surgery-related data
were obtained from patient case notes and the in-house
electronic patient administration system (iSOFT 2010).
The retrospective arm of the study extended from 1st April
2009 to 30th June 2010 and included 616 consecutive
patients of whom 27 were on warfarin at the time of
admission (pre-protocol group). The prospective arm
extended from 1st September 2010 to 31st December 2012
and included 855 consecutive hip fracture patients, of
whom 40 were on warfarin at admission. Patients admitted
during the months of July and August 2010 (n = 97) were
excluded from the analysis to allow development and
implementation of the warfarin protocol.
Demographic data collected for all patients included
age, gender and preoperative residential status. Clinical
data, including ASA (American Society of Anaesthesiolo-
gy) grade, indication for anticoagulation, INR before and
after surgery and prior to discharge, pre- and postoperative
haemoglobin (Hb) levels, time interval from admission to
vitamin K administration, time interval from vitamin K
administration to operation and from operation to recom-
mencement of warfarin were collected on all patients. Any
adverse effects of vitamin K administration, including
allergic reactions or thromboembolic complications were
noted. Pre- and postoperative Hb levels were measured
immediately prior to surgery and at 24 h following surgery,
respectively and the peri-procedural fall in Hb was calcu-
lated by subtracting the postoperative Hb level from the
preoperative Hb level.
Surgery related data, including the type of implant used,
grade of operating surgeon/anaesthetist, the type of
anaesthetic technique used and hospital length of stay were
also collected. Data on the grade of surgeon and anaes-
thetist was categorised into two groups: consultant grade or
other (including all types of trainees and staff grade doc-
tors). The type of anaesthetic technique was also catego-
rised into two groups: general anaesthesia with or without a
nerve block (GA) and regional anaesthesia including
spinal, epidural or combined spinal-epidural anaesthetic
(RA). Statistical analysis was undertaken to compare dif-
ferences between the two groups.
Descriptive statistics of median (interquartile range, IQR)
and mean (standard deviation, SD) were calculated for
continuous variables, whereas proportions as percentages
were used for categorical variables. The Mann–Whitney
(MW) test was used to compare continuous variables
whereas Fisher’s exact (FE) and Chi-square (CS) tests were
used to compare categorical variables on univariate analysis.
All statistical analyses were performed using XLSTAT
version 7.0 software (Addinsoft, New York, NY, USA).
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Results
Twenty-seven patients in the pre-protocol group (27/616,
4.4 %) and 40 patients in the post-protocol group (4.7 %,
40/855) were on warfarin at admission. The demographic,
clinical and surgery-related characteristics of patients in
both groups are presented in Table 1. No significant dif-
ferences in age (p = 0.67), gender (p = 1.00), preopera-
tive residential status (p = 0.76), ASA grade (p = 0.06),
type of implant used (p = 0.85) grade of operating surgeon
Fig. 1 Algorithm for reversal
of warfarin therapy in hip
fracture patients
Fig. 2 Algorithm for
reintroduction of warfarin
following surgery
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(p = 0.80) or anaesthetist (p = 0.40) and type of anaes-
thetic technique used (p = 0.80) were noted between the
two groups. There was a significant difference in the
indications for anticoagulation therapy between the two
groups with a higher proportion of patients in the post-
protocol group noted to have atrial fibrillation compared to
the pre-protocol group (34 vs. 16 respectively, p = 0.001).
The mean INR levels recorded at admission, preoperatively
and at discharge in both groups are shown in Table 1; no
significant differences in INR levels were noted between
the two groups. No significant difference in the peri-pro-
cedural fall in Hb was identified between the two groups
(mean fall in Hb was 1.9 g/dl (SD 1.1) in the pre-protocol
group vs. 2.3 g/dl (SD 1.2) in the post-protocol group,
p = 0.34).
There was a significant reduction in the median AOT
(p \ 0.001) from 73 h (IQR 46–105) in the pre-protocol
group to 37.7 h (IQR 28–45) in the post-protocol group
(Table 2). Both the admission to vitamin K administration
time [18 h (IQR 8–24) in pre-protocol group vs. 7.6 h (IQR
4–13) in post-protocol group, p = 0.003] and the vitamin
K administration to operation time [64 h (IQR 24–75) in
pre-protocol group vs. 29.3 h (IQR 17–37) in post-protocol
group, p = 0.005], reduced significantly after implemen-
tation of the protocol. The proportion of patients operated







Age, median (IQR) 81 (77–85) 81.5 (76–88) 0.67
Gender
Male 9 (33 %) 18 (45 %) 1.0*
Female 14 (67 %) 26 (55 %)
Residential status
Own home 19 (70.3 %) 30 (75 %) 0.76
Residential home 6 (22.2 %) 6 (15 %)
Nursing home 2 (7.4 %) 3 (7.5 %)
In-patient 0 (0 %) 1 (2.5 %)
ASA grade
I 0 (0 %) 0 (0 %) 0.06
II 12 (44.4 %) 7 (17.5 %)
III 9 (33 %) 19 (47.5 %)
IV 6 (22.2 %) 14 (35 %)
Indication for warfarin therapy
Atrial fibrillation 16 (59.3 %) 34 (85 %) 0.001
Pulmonary embolism 6 (22.2 %) 3 (7.5 %)
Deep venous thrombosis 3 (11.1 %) 2 (5 %)
Others (thrombocytosis/
valve replacement)
2 (7.4 %) 1 (2.5 %)
INR, mean (SD)
At Admission 3.4 (3.6) 3.3 (2.6) 0.08
Preoperative 1.2 (0.2) 1.3 (0.2) 0.05
At Discharge 2.3 (0.7) 2.4 (0.8) 0.73
Hb level (g/dl), mean (SD)
Preoperative Hb 12.3 (1.5) 12.9 (1.9) 0.12
Postoperative Hb 10.3 (0.3) 10.6 (0.3) 0.57
Fall in Hb 1.9 (1.1) 2.3 (1.2) 0.34
Type of implant
Hemiarthroplasty 13 (48.1 %) 20 (50 %) 0.85
DHS/CHS 11 (40.7 %) 14 (35 %)
Intra-medullary fixation 3 (11.1 %) 6 (15 %)
Surgeon grade
Consultant 11 (40.7 %) 15 (37.5 %) 0.80*
Other 16 (59.3 %) 25 (62.5 %)
Anaesthetist grade
Consultant 26 (96.3 %) 40 (100 %) 0.40*
Other 1 (3.7 %) 0 (0 %)
Anaesthesia technique
General 14 (51.8 %) 23 (57.5 %) 0.80*
Regional 13 (48.2 %) 17 (42.5 %)
IQR interquartile range, SD standard deviation, Hb haemoglobin, INR
international normalised ratio, DHS dynamic hip screw, CHS cannulated
hip screw
* Fisher’s exact test
 Chi-square test
 Mann–Whitney test







Route of VK administration
Intravenous 12 (44.4 %) 36 (90 %) \0.001
Oral 3 (11.1 %) 0 (0 %)












68.0 (50–100) 73.8 (51–100) 0.90
Admission to operation
time (h), median (IQR)
73 (46–105) 37.7 (28–45) \0.001
Surgery within 48 h of
presentation
8 (30 %) 32 (80 %) \0.001
Hospital length of stay 21.2 (16–36) 19.2 (14–33) 0.77
IQR interquartile range, VK vitamin K
 Chi-square test
 Mann–Whitney test
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on within 48 h of admission increased from 30 % (8/27) in
the pre-protocol group to 80 % (32/40) in the post-protocol
group (p \ 0.001). A surgical delay of more than 48 h due
to a prolonged INR ([1.5) occurred in 14 (52 %) patients
in the pre-protocol group compared to 5 (12.5 %) patients
in the post-protocol group.
The warfarin recommencement time following surgery
in the pre-protocol group was 68 h (IQR 25–100) com-
pared to 73.8 h (IQR 51–100) in the post-protocol group
(p = 0.90). The overall median length of hospital stay
decreased from 21.2 days (IQR 6–35) in the pre-protocol
group to 19.2 days (IQR 14–33) in the post-protocol group
(p = 0.77). These differences were not statistically
significant.
In the pre-protocol group, vitamin K was administered
for warfarin reversal in 15 (55.6 %) patients preoperatively
(12 received intravenous vitamin K whereas 3 received oral
vitamin K). Of these 15 patients that received vitamin K, 6
required a second dose to correct the INR to \1.5. In
comparison, 36 (90 %) patients in the post-protocol group
received intravenous vitamin K for warfarin reversal pre-
operatively; 21 required a second dose and another 6
required a third dose for correction of INR prior to surgery.
Of the four patients that did not receive vitamin K in the
post-protocol group, three had an INR of\1.5 at admission
and one had an elevated INR of 17.5 which was treated
with prothrombin concentrate complex (PCC). No adverse
reactions to vitamin K administration were noted in either
of the two groups. There were no thromboembolic events
recorded for any of the patients in either group at 3 months
follow-up.
Discussion
Our results show that implementation of a locally devel-
oped perioperative anticoagulation management protocol
utilising intravenous vitamin K significantly reduced
admission to vitamin K administration time and vitamin K
administration to operation time in hip fracture patients
who were on warfarin therapy at the time of admission. As
a result, hip fracture surgery at our institution was expe-
dited and significant reductions in the admission to oper-
ation time were seen. Delays in surgery due to a prolonged
INR ([1.5) were also reduced. Use of the protocol did not
appear to reduce overall hospital stay in our cohort or the
time taken for recommencing warfarin postoperatively.
Perioperative administration of intravenous Vitamin K was
not associated with any thromboembolic or allergic
complications.
There has been an exponential increase in the number of
patients taking warfarin over the last two decades. This
increase can partly be attributed to a rise in the prevalence
of atrial fibrillation due to an ageing population and partly
to improvements in the diagnosis and management of
patients with arrhythmias in primary care. We found the
overall prevalence of warfarin use to be 4.6 % (67/1,471)
in our cohort of hip fracture patients.
There is growing evidence that provision of protocol- or
checklist-driven standardised care can improve clinical
outcomes [14–16]. Ashouri et al. [6] demonstrated that lack
of a standardised protocol resulted in variations in the
anticoagulation reversal regime and consequently lead to
delays in hip fracture surgery. The Scottish National audit
showed that the proportion of medically fit hip-fracture
patients operated on within 24 h of admission rose from 86
to 97 %, following introduction of protocols to standardise
management [17]. Our results demonstrate that the pro-
portion of patients that underwent surgery within 48 h of
presentation increased from 30 % before the existence of a
standardised protocol to 80 % after its implementation.
Simply waiting for the INR to fall to acceptable levels in
hip fracture patients who are on warfarin may lead to
significant delays in surgery [5, 6, 14, 18–20]. There is a
clear need for interventions to reduce the INR urgently in
these patients, however, no consensus exists on the timing,
route or dosage of anticoagulation reversal. UK guidance
on perioperative management of hip-fracture patients on
warfarin therapy is confusing at worst and non-conclusive
at best. The British Orthopaedic Association (BOA) rec-
ommends that the INR should be corrected to 1.5 or lower
prior to surgery [4] but does not support the use of vitamin
K or fresh frozen plasma (FFP) due to a lack of high-level
evidence. Guidelines published by the British Committee
for Standards in Haematology (BCSH) do not make spe-
cific references to the perioperative management of war-
farin in hip fracture patients [7]. Although they appear to
support warfarin reversal with intravenous vitamin K for
urgent surgery, the safe or effective dose of vitamin K is
not specified. The Scottish Intercollegiate Guidelines Net-
work (SIGN) guidelines suggest that orally administered
low-dose vitamin K (1–2.5 mg) can take up to 24 h to
reverse the effects of warfarin [2]. They recommend that
the route and dose of vitamin K should depend on the INR
at admission and urgency of surgery. Our study has shown
that the use of intravenous vitamin K at doses of 1 mg
administered at 24-h intervals in low risk patients can
reduce surgical delay in hip-fracture patients safely. Fur-
thermore, we did not find any significant adverse reactions
to intravenous vitamin K or an increase in thromboembolic
events at 3 months post-surgery.
Development of the protocol utilised in the current study
was driven by two factors: the existence of uncertainty in
the perioperative management of hip fracture patients on
warfarin therapy due to non-specific national guidelines
and a local retrospective audit that showed suboptimal
J Orthopaed Traumatol (2014) 15:21–27 25
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management of hip-fracture patients because of wide
variations in management by clinicians; some choosing the
‘wait and watch’ approach to correct INR, some using oral
vitamin K while others used intravenous vitamin K for
warfarin reversal. Our protocol was influenced by BCSH
recommendations; however, three distinctive features can
be identified:
1. Thromboembolic risk stratification of patients preop-
eratively into two groups (low and high risk) with
different action triggers for warfarin discontinuation,
reversal and bridging.
2. Use of a standardised 1-mg dose of intravenous
vitamin K.
3. Bleeding risk stratification of patients postoperatively
into two groups (simple-uncomplicated and extensive-
complicated) with separate action triggers for re-
warfarinisation.
The primary concern regarding discontinuation of war-
farin and its reversal with vitamin K is the predisposition of
patients to thromboembolic events such as stroke, deep
vein thrombosis, pulmonary embolism and prosthetic heart
valve thrombus formation. It is estimated that in high-risk
patients, the absolute risk of thromboembolic events within
6–8 days of stopping warfarin is approximately 0.3 % [21].
We classified patients on warfarin into low- and high-risk
groups depending on the indication for warfarin therapy,
and linked action triggers for vitamin K administration to
low risk patients only. High-risk patients were managed
after multidisciplinary discussion between surgeons,
anaesthetists and haematologists. Only one high-risk
patient was identified in our study. We believe that with-
holding vitamin K in high-risk patients does not represent
suboptimal care. It reflects a safe approach to managing
these patients in whom valve thrombosis can be a devas-
tating complication [22].
Five different approaches to correction of INR have
been proposed; rapid with PCC, fast with FFP, prompt with
intravenous vitamin K, slow with oral vitamin K and ultra-
slow with simple discontinuation of warfarin [23]. We did
not consider the first two approaches because of significant
safety concerns associated with use of blood-derived pro-
ducts and the non-emergency nature of hip fracture sur-
gery. Although simply discontinuing warfarin can
eventually lead to a drop in INR, this may take up to 5 days
[24]. Both the oral and intravenous routes are considered
equally effective for vitamin K administration but the oral
route has been shown to be slower for INR correction and
can delay surgery by more than 24 h [25]. It is for these
reasons that we chose the intravenous route for our pro-
tocol. We chose a 1-mg dose of vitamin K for warfarin
reversal. Although higher doses could potentially offer
faster INR correction, they also confer increased warfarin
resistance, making re-warfarinisation more difficult post-
operatively [11, 26].
Warfarin could be recommenced safely within 24 h
following surgery provided adequate haemostasis had been
achieved [7]. Despite implementation of the protocol, we
did not see a significant difference in the postoperative
warfarin recommencement time. This could be attributed to
inconsistencies in application of the protocol by clinical
staff prescribing warfarin on the wards and has been
highlighted to the orthogeriatric and ward-based surgical
teams. We hypothesise that a possible reason for reluctance
among clinicians to recommence warfarin within 24 h after
surgery is a lack of awareness on intraoperative haemo-
stasis. We have therefore asked surgeons to clearly docu-
ment satisfaction with haemostasis in operative case notes
and include orders to restart warfarin within 24 h in the
postoperative plan. Although we noted a 2-day reduction in
median length of stay in the post-protocol group, this
decrease was not found to be statistically significant. We
believe that further reductions may well be seen if strict
adherence to the postoperative warfarin recommencement
regimen could be ensured, however, we do recognise that
length of stay in hip fracture surgery patients is
multifactorial.
Our study is limited by its observational nature and the
use of a retrospective series of patients as the control
group. We recognise that there were significant differences
between the pre- and post-protocol groups with respect to
the indications for warfarin, however, patients in both
groups were well matched for age, gender and ASA grade.
We conclude that variations in the management of hip
fracture patients on warfarin therapy at admission could be
reduced by introduction of a simple, evidence-based pro-
tocol, and that implementation of such a standardised tool
using intravenous vitamin K is a safe and effective method
to expedite hip fracture surgery and prevent delays.
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